Morganti S, Chu X, Ballinger TJ, et al. A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer. Clinical breast cancer. 2025;25(6):566-574.e2. doi:10.1016/j.clbc.2025.05.009